



MEETING ABSTRACT

Open Access

P01-034 – Cancer in FMF: a population based study Israel

R Brenner¹, S Kivity^{2,3}, Y Shinar⁴, I Iphshitz⁵, E Ben-Chetrit⁶, A Livneh^{2,4,7}, B Zvi^{8*}

From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID) Lausanne, Switzerland. 22-26 May 2013

Introduction

Recurrent or persistent inflammation, featuring familial Mediterranean fever (FMF), may induce, promote, or influence susceptibility to carcinogenesis. However, the association between FMF and malignancy was rarely described before.

Objectives

To assess the prevalence of malignancy in FMF.

Methods

Demographic data of FMF patients, followed in the national FMF center at Sheba medical center (n=8352) and Hadassah Medical Center (n=1083) were obtained from FMF patient hospital registries. The prevalence of cancer in the general population, and in the study registries was attained from the cancer registry of Israel and analyzed according to age, origin, and cancer type. The Standardized **incidence** rates (SIR) of the different cancers in FMF patients were calculated and compared to the cancer SIR of the parallel Israeli ethnic population.

Results

Of 9435 FMF patients (4696 men, 4739 female), 363 developed cancer during the years 1970- 2011. FMF female patients developed significantly more lymphoma (Hodgkin and non-Hodgkin) and in-situ cervical cancer than the matched general population, SIR 2.07 (95% CI 1.12-2.99) and 1.86 (95% CI 1.20-2.51), respectively. In contrast, male and female with FMF had a lower gastrointestinal cancer incidence, SIR 0.68 (95% CI 0.42-0.95) and 0.63 (95% CI 0.36-0.90).

Conclusion

The risk for lymphoma and in-situ cervical cancer is increased about twice in FMF. Understanding the underlying mechanism (inflammation? Colchicine? Genetic predisposition?) may improve patient prognosis.

Disclosure of interest

None declared.

Authors' details

¹Cancer Unit, Edith Wolfson Medical Center, Holon, Tel Aviv, Israel.

²Rheumatology Unit, Zavladoch center of autoimmune disease, Israel.

³Department of Medicine A and C, Sheba Medical Center, Ramat-Gan, Israel.

⁴Heller Institute of Medical Research, Sheba Medical Center, Ramat-Gan, Israel.

⁵Israeli National Cancer Registry, Ministry of Health, Israel.

⁶Department of Medicine A, Hadassah-Hebrew University and Medical Center, Jerusalem, Israel.

⁷Department of Medicine F, Sheba Medical Center, Ramat-Gan, Israel.

⁸Rheumatology Unit at Zavladoch center of autoimmune disease, Heller Institute of Medical Research, Department of Medicine F, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.

^{*}Corresponding author: Brenner R, Email: brenner@sheba.health.gov.il

Published: 8 November 2013

doi:10.1186/1546-0096-11-S1-A38

Cite this article as: Brenner *et al.*: P01-034 – Cancer in FMF: a population based study Israel. *Pediatric Rheumatology* 2013 11 (Suppl 1):A38.

⁸Rheumatology Unit at Zavladoch center of autoimmune disease, Heller Institute of Medical Research, Department of Medicine F, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

Full list of author information is available at the end of the article